Intravenous Immunoglobulin (IVIG)
The most widely used first-line treatment for CIDP, with Level A evidence
Route
Intravenous infusion
Frequency
Every 3–4 weeks (maintenance)
Setting
Infusion center or hospital
FDA Status
FDA-approved for CIDP
Educational use only. This page explains how IVIG works based on clinical guidelines and trial data. It cannot replace your neurologist. All treatment decisions must be made with your medical team.
How IVIG Works
IVIG (intravenous immunoglobulin) contains pooled IgG antibodies collected from thousands of plasma donors. In CIDP, it works by modulating the overactive immune system through several simultaneous mechanisms, suppressing the abnormal attack on peripheral nerve myelin rather than replacing a deficiency.
- •Fc receptor blockade: saturates Fcγ receptors on macrophages and dendritic cells, preventing them from targeting myelin-coated nerves
- •Complement inhibition: blocks complement cascade activation on nerve surfaces, reducing inflammatory nerve damage
- •Anti-idiotypic antibodies: the pooled IgG contains antibodies that neutralize the specific pathogenic antibodies driving demyelination in each patient
- •Regulatory T-cell modulation: shifts the immune system balance toward tolerance by expanding regulatory T-cell populations
- •FcRn saturation: occupies the FcRn recycling receptor, accelerating clearance of pathogenic IgG (shared mechanism with Vyvgart Hytrulo)
Clinical Evidence
IVIG is the most commonly used first-line treatment for CIDP with Level A evidence — the highest level in the EAN/PNS 2021 clinical practice guideline. Approximately 50–60% of CIDP patients show significant clinical improvement. The PATH study established that continuing IVIG maintenance therapy significantly reduces relapse risk compared to stopping treatment.
| Metric | Value | Source |
|---|---|---|
| Response rate | ~50–60% | Pooled IVIG CIDP trials |
| Relapse reduction vs. placebo | 61% | PATH Study, NEJM 2017 |
| Evidence level | Level A (strongest) | EAN/PNS 2021 guideline |
| Time to first response | Days to 4 weeks | EAN/PNS 2021 guideline |
| Loading dose | 2 g/kg over 2–5 days | Standard protocol |
| Maintenance dose | 1 g/kg every 3–4 weeks | Standard protocol |
Response is defined as meaningful improvement in strength, sensation, or functional scores (e.g., INCAT disability score, MRC sum score). Patients who do not respond to an adequate loading dose trial are less likely to benefit from continued IVIG and may need to switch treatments.
"Wearing off" — the return of symptoms in the 1–2 weeks before the next infusion — is common and indicates the dosing interval may be too long. If you notice this pattern, document it and discuss dose adjustment or a switch to weekly SCIg with your neurologist.
Side Effects
Common
- •Headache (most common — often caused by rapid infusion rate)
- •Fatigue lasting 1–2 days after infusion
- •Low-grade fever or chills during infusion
- •Nausea
- •Flushing
- •Muscle aches
Serious (less common)
- •Aseptic meningitis: severe headache and neck stiffness 12–24 hours after infusion
- •Thromboembolic events (blood clots): risk higher with high doses in older patients or those with cardiovascular risk factors
- •Hemolytic anemia: destruction of red blood cells (uncommon)
- •Acute kidney injury: more common with sucrose-stabilized IVIG formulations; use sucrose-free products in patients with kidney disease
- •Anaphylaxis: rare; significantly higher risk in patients with IgA deficiency — screen before first dose
Pre-medication with acetaminophen (1000mg) and diphenhydramine (25–50mg) 30–60 minutes before infusion reduces mild reactions. Slowing the infusion rate helps with headache and flushing. If headaches are severe or recurrent, ask your neurologist about switching to subcutaneous immunoglobulin (SCIg), which has far fewer systemic side effects due to its slower absorption.
Pros & Cons
Advantages
- ✓Strongest evidence base — Level A recommendation in all major guidelines
- ✓Well-established safety profile with decades of real-world use
- ✓Effective for most CIDP variants including typical, pure sensory, and multifocal motor neuropathy
- ✓Multiple FDA-approved products available, reducing shortage risk
- ✓Covered by most insurance plans (Medicare, Medicaid, commercial)
- ✓Response is often rapid — improvement within days to weeks
Drawbacks
- –Requires IV access and 3–6 hours at an infusion center every 3–4 weeks
- –Wearing-off effect: symptoms return before the next infusion in many patients
- –Plasma-derived — depends on donor supply; occasional shortages occur
- –Contraindicated in IgA deficiency (anaphylaxis risk)
- –Headache and fatigue side effects can be disruptive
- –Prior authorization required; may need documentation of nerve conduction study results
Insurance & Access
- →Generally covered by Medicare Part B (outpatient) and most commercial insurers for documented CIDP
- →Prior authorization almost always required — your neurologist's office must submit nerve conduction study results, functional impairment documentation, and often an ICD-10 code of G61.81
- →Some insurers require step therapy — trying corticosteroids first — which may be waived if you have pure motor CIDP (where steroids are contraindicated) or documented steroid intolerance
- →If denied, the EAN/PNS 2021 guideline's Level A recommendation for IVIG is strong grounds for appeal
- →Home infusion of IVIG is possible for stable patients and may be covered; discuss with your infusion company
Have a question about IVIG?
Ask the AI assistant for more detail — dosing questions, wearing-off, insurance appeals, how IVIG compares to other options, and more.
Ask the AI →Other CIDP Treatments
Vyvgart Hytrulo
First FDA-approved FcRn inhibitor for CIDP — a 30-second weekly injection at home
SCIg
Weekly home injections that eliminate infusion center visits and the wearing-off effect
Plasma Exchange
A fast-acting procedure that physically removes harmful antibodies from the blood
Corticosteroids
Oral or IV steroids that broadly suppress immune activity — effective but with long-term trade-offs
Sources
- van den Bergh PYK, et al. EAN/PNS Guideline on CIDP. Eur J Neurol. 2021;28(11):3556–3583.
- van Schaik IN, et al. Subcutaneous immunoglobulin for maintenance treatment in CIDP (PATH Study). N Engl J Med. 2018;378(9):802–812.
- FDA. Approved IVIG products for CIDP. Drugs@FDA.